Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy | Synapse
January 12, 2022Open Access
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy
Key Points
Key points are not available for this paper at this time.
Abstract
The results of this cohort study suggest that the development of cirAEs is strongly associated with response to ICI therapy and patient survival.